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a b s t r a c t
Exposure to light contributes to the development and progression of retinal degenerative diseases. However,
the mechanisms underlying light-induced tissue damage are not fully understood. Here, we examined the role
of angiotensin II type 1 receptor (AT1R) signaling, which is part of the renin–angiotensin system, in light-
induced retinal damage. Light-exposed Balb/c mice that were treated with the AT1R blockers (angiotensin II
receptor blockers; ARBs) valsartan, losartan, and candesartan before and after the light exposure exhibited
attenuated visual function impairment, compared to vehicle-treated mice. This effect was dose-dependent and
observed across the ARB class of inhibitors. Further evaluation of valsartan showed that it suppressed a
number of light-induced retinal effects, including thinning of the photoreceptor cell layer caused by apoptosis,
shortening of the photoreceptor cell outer segment, and increased levels of reactive oxygen species (ROS). The
role of ROS in retinal pathogenesis was investigated further using the antioxidant N-acetyl-L-cysteine (NAC).
Treatment of light-exposed mice with NAC before the light exposure suppressed the visual function
impairment and photoreceptor cell histological changes due to apoptosis. Moreover, treatment with valsartan
or NAC suppressed the induction of c-fos (a component of the AP-1 transcription factor) and the upregulation
of fasl (a proapoptotic molecule whose transcript is regulated downstream of AP-1). Our results suggest that
AT1R signaling mediates light-induced apoptosis, by increasing the levels of ROS and proapoptotic molecules
in the retina. Thus, AT1R blockade may represent a new therapeutic approach for preventing light-induced
retinal neural tissue damage.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
Light is indispensable for vision; however, it may also accel-
erate age-related diseases resulting in visual impairment. In fact,
light exposure is a reported risk factor associated with the
progression of age-related macular degeneration [1] and retinitis
pigmentosa [2], major causes of blindness. Recent reports have
demonstrated some of the pathological effects of light exposure on
the development of these diseases [3,4]. However, many of the
underlying molecular mechanisms of light-induced tissue damage
remain elusive and are not fully understood.
The pathogenic mechanisms associated with acute exposure to
excessive light that result in photoreceptor cell apoptosis and retinal
damage have been extensively studied [2,5–7]. The process is initiated
by the enhanced metabolism of rhodopsin, a visual pigment, in
response to excessive light exposure [8]; the resulting excessive
activation of the visual cycle, inwhich the light-transformed rhodopsin
chromophore is enzymatically converted to 11-cis-retinal, induces
photoreceptor cell apoptosis [8]. Genetically induced rhodopsin deﬁ-
ciency [9] or inhibition of the visual cycle by in vivo treatment with
13-cis-retinoic acid can block the apoptosis and retinal damage [10]. It
was also shown that c-Fos, a component of the transcription factor
activator protein-1 (AP-1)1, is required for the photoreceptor cell loss,
as shown by the lack of retinal photodamage in c-fos-knockout mice
[11,12]. Light-induced retinal damage also involves DNA fragmentation
[13–15], calcium inﬂux [16], and mitochondrial dysfunction [12,17].
These events can all be inhibited by decreasing the light that reaches
the retina with light-blocking glasses [18] or intraocular lenses [19,20].
We are interested in identifying complementary protective approaches
that can be used in combination with light-blocking materials.
Here, we focused on the renin–angiotensin system (RAS), which is
activated in response to environmental stimuli and is characterized
as a stress response system [21]. Angiotensin II type 1 receptor (AT1R)
signaling is well known for causing tissue damage [22], as shown
in the cardiovascular system [23,24] and kidneys [25,26], as well as
in the retina under inﬂammatory conditions [27–32]. AT1R is a
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seven-transmembrane, G-protein-coupled receptor that induces var-
ious intracellular signaling cascades [33]. We hypothesized that AT1R
signaling may be involved in mediating light-induced tissue damage.
AT1R blockers (angiotensin II receptor blockers; ARBs) such as
valsartan, losartan, and candesartan, all of which bind to the AT1R
to suppress its signal, are standard treatments for hypertension.
Recent reports show that ARBs have tissue-protective effects in
addition to reducing blood pressure [30,32,34–36]. ARB-targeted
diseases are induced by oxidative stress [37–40], similar to light-
induced retinal degeneration [15,41].
In this study, we analyzed whether the light-induced ROS accu-
mulation in the retina and resulting visual function impairment are
mediated by AT1R signaling, focusing on the molecular mechanisms
underlying light-induced photoreceptor cell apoptosis.
Materials and methods
Animals
Six-week-old Balb/c male mice were purchased (CLEA Japan,
Tokyo, Japan) and housed in an air-conditioned room maintained
at 2272 1C under a 12-h dark/light cycle (light on from 0800 to
2000 hours), with free access to a standard diet (CLEA Japan) and
tap water. All animal experiments were conducted in accordance
with the Association for Research in Vision and Ophthalmology
Statement for the Use of Animals in Ophthalmic and Vision Research
and the guidelines of the Animal Care Committee of Keio Uni-
versity (Approval No. 08002).
Light exposure
The light-exposure experiments were performed as described
previously [15,42]. Brieﬂy, before light exposure, the 6- to 7-week-
old mice were allowed to rest for several days and were then dark-
adapted by maintaining them in complete darkness for 12 h. Their
pupils were dilated with a mixture of 0.5% tropicamide and 0.5%
phenylephrine (Mydrin-P; Santen Pharmaceutical, Osaka, Japan)
just before exposure to light. The mice were then exposed to 5000
lux from a white ﬂuorescence lamp (FHD100ECW, Panasonic,
Osaka, Japan) for 1 h (starting at 0900 hours), in a dedicated
exposure box maintained at 2272 1C, containing stainless steel
mirrors on each wall and on the ﬂoor (Tinker N, Kyoto, Japan).
After light exposure, the mice were returned to their cages and
maintained under dim cyclic light (5 lux, 12 h on/off) until they
were euthanized at the time of sampling at various time points,
according to each experimental protocol. Control mice were also
maintained under dim cyclic light and euthanized at the time of
sampling.
Administration of ARBs or N-acetyl-L-cysteine (NAC)
Valsartan (LKT Laboratories, St. Paul, MN, USA) and candesartan
(Sigma–Aldrich, St. Louis, MO, USA) were solubilized in dimethyl
sulfoxide (Sigma–Aldrich), followed by dilution with phosphate-
buffered saline (PBS). Losartan (Sigma–Aldrich) was solubilized in
distilled water, followed by dilution with PBS. Mice were separated
into treatment groups and intraperitoneally injected with either
ARB (valsartan, 5, 20, 200 mg/kg; candesartan, 0.5, 2, 20 mg/kg;
losartan, 3.125, 12.5, 125 mg/kg) or vehicle, twice, just before and
after light exposure. The doses were adjusted to deliver equally
potent doses of the ARBs [43].
For experiments with the antioxidant, NAC (Nakalai Tesque,
Kyoto, Japan), mice were separated into treatment groups and
intraperitoneally injected with either NAC diluted with PBS (250
or 500 mg/kg) or vehicle, twice, before dark adaptation and before
light exposure.
Electroretinogram (ERG)
The ERG was performed as previously described [44–46]. Brieﬂy,
mice were dark-adapted for at least 12 h, maintained under dim red
illumination, and then anesthetized with 70 mg/kg pentobarbital
sodium (Dainippon Sumitomo Pharmaceutical, Osaka, Japan). The
mice were placed on a heating pad throughout the experiment. The
pupils were dilated with one drop of a mixture of 0.5% tropicamide
and 0.5% phenylephrine (Santen Pharmaceutical). The ground elec-
trode was placed on the tail, and the reference electrode was placed
in the mouth. Active electrodes were gold wires placed on the
cornea. Electrical responses were recorded (PowerLab System 2/25;
AD Instruments, NSW, Australia) and differentially ampliﬁed and
ﬁltered through a digital bandpass ﬁlter ranging from 0.313 to
1000 Hz to yield a- and b-waves. Light pulses of 3.20 cd-s/m2 and
4-ms duration were delivered through a commercial stimulator
(Ganzfeld System SG-2002; LKC Technologies, Gaithersburg, MD,
USA). Electrode impedance was checked before and after each
measurement in all animals using a built-in feature of the instru-
ment. Implicit times of the a- and b-waves were measured from the
onset of the stimulus to the peak of each wave. The amplitude of the
a-wave was measured from the baseline to the trough of the a-wave,
and the amplitude of the b-wave was from the trough of the a-wave
to the peak of the b-wave. Each treatment group consisted of six
animals, and all groups were analyzed 6 days after light exposure, the
time point at which clear changes in ERG responses were previously
found to occur [15,42].
Measurement of outer nuclear layer (ONL) thickness and outer
segment (OS) length of the retina
The eyes were enucleated and immediately frozen in Tissue-
Tek OCT compound (Sakura Finetek Japan, Tokyo, Japan). Unﬁxed
cryosections (6 μm thick) that included the optic nerve head were
ﬁxed in 4% paraformaldehyde (PFA) and stained with hematoxylin
and eosin (H-E). The ONL thickness was measured at each point
from the optic nerve head to the most peripheral region of the
retina using the ImageJ program (developed by Wayne Rasband,
National Institutes of Health, Bethesda, MD, USA; available at
http://rsb.info.nih.gov/ij/index.html), and the average values were
calculated. The OS length was measured 750 μm from the optic
nerve in the posterior upper retina using ImageJ. All of the sections
were examined under a microscope equipped with a digital
camera (Biorevo BZ-9000, Keyence, Osaka, Japan). Each group
consisted of six animals, and all groups were analyzed 6 days
after light exposure, the time point previously shown to exhibit a
clear change in retinal morphology after light exposure [15,42].
TdT-mediated dUTP nick-end labeling
Mice were anesthetized with pentobarbital sodium (70 mg/kg).
Subsequently, the eyes were enucleated and ﬁxed in 4% PFA
overnight at 4 1C. After ﬁxation, the tissues were processed and
embedded in Tissue-Tek OCT compound (Sakura Finetek Japan).
Cryosections (6 μm thick) that included the optic nerve head were
prepared, and the TdT-mediated dUTP nick-end labeling (TUNEL)
assay was performed using the ApopTag red apoptosis detection
kit (Millipore, Bedford, MA, USA) according to the manufacturer’s
protocol. Nuclei were stained with 10 μg/ml Hoechst bisbenzimide
33258 (Sigma–Aldrich). Fluorescence images were obtained using
confocal ﬂuorescence microscopy (FV 1000, Olympus, Tokyo,
Japan), and TUNEL-positive cells in the ONL were counted. Each
treatment group consisted of six animals and all groups were analyzed
T. Narimatsu et al. / Free Radical Biology and Medicine 71 (2014) 176–185 177
Fig. 1. Suppression of light-induced visual function impairment by ARBs. Analysis of full-ﬁeld ERG after light exposure. (A) Representative wave forms of the ERG from an
individual mouse treated with one of the ARBs, valsartan, in each dosage group in response to one ﬂash. (B, C) Amplitudes of the a-wave and b-wave were decreased 6 days
after light exposure, and these changes were suppressed by treatment with ARBs in a dose-dependent manner. (D, E) No differences were observed in the a-wave or b-wave
implicit times. ERG, electroretinogram; ARBs, angiotensin II type 1 receptor blockers; C, control; LE, light exposure; val, valsartan; los, losartan; can, candesartan. n ¼ 6 in
each group. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc test. **P o 0.01, *P o 0.05.
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2 days after light exposure, the time point at which a clear change in
photoreceptor cell number was previously detected [15,42].
Measurement of ROS
ROS measurement was performed as described previously
[15,46]. Brieﬂy, the eyes were enucleated and immediately frozen
in Tissue-Tek OCT compound (Sakura Finetek Japan). Unﬁxed cryo-
sections (6 μm thick) were incubated with 5 mM dihydroethidium
(DHE; Life Technologies, Carlsbad, CA, USA) for 10 min at room
temperature. DHE reacts with intracellular superoxide anion and is
converted to the red ﬂuorescent compound ethidium. Fluorescence
images were obtained using confocal ﬂuorescence microscopy (FV
1000, Olympus) using the equal exposure conditions among the
groups; the staining intensity in the ONL was measured at two points
in the posterior retina, which were vertically 250 μm away from the
optic disc, using the ImageJ program, and averaged. Each treatment
group consisted of six animals and all groups were analyzed 1 h after
light exposure, the time point at which a clear increase in retinal ROS
was previously observed [15].
Quantitative real-time RT-PCR
The eyes were enucleated and the retinas were placed in 100 μl
of TRIzol reagent (Life Technologies) to extract the total RNA.
Complementary DNA was generated by adding 1 μg of the total
RNA to SuperScript VILO master mix (Life Technologies) and
performing reverse transcription according to the manufacturer’s
instructions. PCR was performed using the StepOnePlus real-time
PCR system (Life Technologies), and the ΔΔCT method was used to
quantify gene expression. The following gene-speciﬁc primers
designed by TaqMan Gene Expression Assays (Life Technologies)
were used: Mm00487425_m1 (fos), Mm00438864_m1 (fasl), and
Cat. No. 4352339E (gapdh). The mRNA levels were normalized to
that of gapdh mRNA. The data from 6 to 12 animals in each group,
analyzed 1 (fos) or 6 h (fasl) after light exposure, are shown. The
time points were selected based on results of preliminary experi-
ments, in which the peak expression was observed at 1 (fos) and
6 h (fasl) after light exposure.
Statistical analysis
All results were expressed as means 7 SD. The values were
processed for statistical analyses (one-way ANOVA with Tukey’s post
hoc test) using SPSS Statistics 21 (IBM, Armonk, NY, USA) software,
and differences were considered statistically signiﬁcant at P o 0.05.
Results
Suppressive effect of ARBs on light-induced visual function
impairment
To evaluate the protective effect of ARBs against the visual
function impairment induced by light exposure, we examined the
ERG recordings of mice treated with ARBs or vehicle just before and
after exposure to light (Fig. 1A–E). In vehicle-treated mice the
amplitudes of both the a-wave (Fig. 1B), which reﬂects photoreceptor
function, and the b-wave (Fig. 1C), which represents subsequent
neuronal signaling, were decreased 6 days after light exposure.
Fig. 2. Suppression of light-induced histological changes in the retina by valsartan. (A) H-E staining of retinal sections 6 days after light exposure. (B) The ONL thickness and
(C) the OS length in the retina of light-exposed mice were reduced compared with those of untreated control mice. This reduction was signiﬁcantly attenuated by valsartan
administration (5 mg/kg). (D, E) TUNEL assay performed 2 days after light exposure. TUNEL-positive cells (red) appeared in the ONL after light exposure. These apoptotic cells
were signiﬁcantly reduced by valsartan administration (5 mg/kg). Hoechst staining of the control was shown as a guide for the retinal layers. GCL, ganglion cell layer; INL,
inner nuclear layer; ONL, outer nuclear layer; OS, outer segment; ■, control mice with no light exposure; ●, light-exposed mice treated with vehicle; ○, light-exposed mice
treated with valsartan. n ¼ 6 in each group. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc test. **P o 0.01, *P o 0.05.
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However, these decreases were attenuated by the administration of
ARBs (valsartan, losartan, or candesartan), in a dose-dependent
manner, indicating that this class of drugs was effective in suppres-
sing the light-induced visual function impairment. Because 5 mg/kg
valsartan was sufﬁcient to produce a protective effect, the following
experiments were performed using this dose of valsartan.
Suppressive effect of valsartan on light-induced photoreceptor
changes
To elucidate the effect of ARBs on retinal histology, light-exposed
mice were treated with either vehicle or valsartan just before and
after light exposure, and retinal sections were prepared and analyzed
by H-E staining (Fig. 2A). Retinal sections prepared from vehicle-
treated mice 6 days after light exposure indicated that the thickness
of the ONL that is composed of photoreceptor cells (Fig. 2B) and the
length of the OS (Fig. 2C) were all decreased. However, these changes
were signiﬁcantly suppressed by valsartan treatment. There were no
obvious changes in the other retinal layers.
Next, we performed TUNEL assays to determine whether the
retinal thinning was mediated by apoptosis. TUNEL-positive apop-
totic cells increased in the retina 2 days after light exposure, and
there were signiﬁcantly fewer TUNEL-positive cells in the retinas
of mice in the valsartan-treated group compared with the vehicle
group (Fig. 2D and E). This result was consistent with valsartan’s
suppression of light-induced ONL thinning shown above.
Inhibitory effect of valsartan on light-induced ROS accumulation
We next analyzed the effects of valsartan on light-induced ROS
levels in the ONL by measuring the ﬂuorescence intensity of DHE,
which increases in the presence of ROS, mainly superoxide anions.
Consistent with our previous reports [15,46], ROS levels in the ONL
of the retina from control mice increased 1 h after light exposure.
However, the ROS levels in the ONL from mice treated with
valsartan just before and after light exposure were substantially
suppressed (Fig. 3A and B).
Inhibitory effect of NAC on light-induced retinal damage
We next investigated whether oxidative stress was involved in
promoting the light-induced retinal damage described above, using
the antioxidant NAC. Interestingly, light-induced changes in ERG
responses (Fig. 4A–E), histological characteristics (Fig. 4F–H), and
photoreceptor cell apoptosis (Fig. 4I and J) were all suppressed by
pretreatment with NAC. Thus, we concluded that oxidative stress also
plays a role in the light-induced retinal damage mediated by AT1R.
Fig. 3. Inhibition of light-induced ROS accumulation by treatment with valsartan. Detection of ROS by DHE staining 1 h after light exposure. (A, B) The ﬂuorescence intensity
of DHE in the ONL measured by ImageJ was increased after light exposure. The light-induced increase in ROS levels was prevented by treatment with valsartan (5 mg/kg).
ONL, outer nuclear layer. n ¼ 6 in each group. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc test. **P o 0.01, *P o 0.05.
T. Narimatsu et al. / Free Radical Biology and Medicine 71 (2014) 176–185180
Suppressive effects of valsartan and NAC on molecular changes in the
retina of light-exposed mice
We further analyzed the light-induced molecular changes in the
retina. In these analyses also, valsartan was administered just before
and after light exposure, and NAC was before light exposure.
c-Fos, a component of the AP-1 transcription factor, is a major
pathogenic factor involved in light-induced photoreceptor damage
[11], and its expression in the retina increases after light exposure
[18]. We therefore measured the c-fos mRNA level in the retinas of
mice treated with vehicle, valsartan, or NAC 1 h after light exposure,
when the ROS levels were signiﬁcantly increased (Fig. 5A and B).
Treatment with either valsartan or NAC suppressed the level of light-
induced c-fos mRNA.
Then, we also examined the expression of fasl, an apoptotic
factor and one of the genes regulated by AP-1 (Fig. 5C and D). The
Fig. 4. Suppression of light-induced retinal damage by treatment with NAC. (A–E) Analysis of full-ﬁeld ERG 6 days after light exposure. (A) Representative wave forms of the
ERG from an individual mouse in each group in response to one ﬂash. (B, C) Amplitudes of the a-wave and b-wave were decreased after light exposure, and these changes
were suppressed by treatment with NAC in a dose-dependent manner. (D, E) No differences were observed in the a-wave or b-wave implicit times. (F) H-E staining of the
retina 6 days after light exposure. The reductions in (G) ONL thickness and (H) OS length in the retina of light-exposed mice were signiﬁcantly attenuated by NAC
administration, in a dose-dependent manner. (I, J) TUNEL assay performed 2 days after light exposure. Light-induced TUNEL-positive cells (red) were signiﬁcantly reduced by
NAC administration. Hoechst staining of the control is shown as a guide for the retinal layers. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; OS,
outer segment; C, control; V, vehicle; ■, control mice with no light exposure; ●, light-exposed mice treated with vehicle; Δ, light-exposed mice treated with NAC at 250 mg/
kg; ○, light-exposed mice treated with NAC at 500 mg/kg. n ¼ 6 in each group. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc test.
**P o 0.01, *P o 0.05, all compared with the data from light-exposed mice treated with vehicle.
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fasl mRNA level was elevated 6 h after light exposure in vehicle-
treated mice, and this increase was attenuated by treatment with
either valsartan or NAC. Taken together, these ﬁndings indicated
that apoptosis-associated molecules were indeed induced in the
retina after light exposure in vivo and that these inductions were
mediated by AT1R and oxidative stress signaling.
Discussion
In this study we demonstrated that light-induced visual impair-
ment was suppressed by the ARB class of drugs administered just
before and after light exposure, in a dose-dependent manner (Fig. 1).
Treatment of mice with one of the ARBs, valsartan, resulted in
attenuated photoreceptor cell apoptosis and degeneration, leading to
reduced thinning of the photoreceptor cell layer (Fig. 2). Valsartan
treatment also prevented the light-induced accumulation of ROS
in the retina (Fig. 3). The suppression of ROS induction by NAC
treatment before light exposure was effective at preventing the light-
induced visual function impairment and the associated histological
changes in photoreceptor cells, in a dose-dependent manner (Fig. 4).
Light-induced increases in the expression of c-fos, a known patho-
genic molecule involved in light-induced retinal damage, and fasl, a
proapoptotic molecule, were also attenuated by treatment with
either valsartan or NAC.
AT1R signaling is known to play a pathogenic role in hyperten-
sion [47,48], atherosclerosis [49], and renal disorders [50,51] and
in promoting focal inﬂammatory diseases of the retina [27–32,52–
54]. In addition, the AT1R is well known to promote proinﬂam-
matory signaling, which can induce inﬂammatory cytokine pro-
duction and/or recruit inﬂammatory cells [55]. Here we report that
light-induced neural tissue damage also involves AT1R signaling,
suggesting that photodamage may be due at least in part to AT1R-
mediated proinﬂammatory signaling.
All ARBs act as antagonists of the AT1R, but because they are
artiﬁcial products, it has been suggested that some of themmay bind
to other receptors, such as CCR2B [56] and PPARγ [57,58]. In addition,
some ARBs are known to function as inverse agonists, meaning they
can suppress the constitutive agonist-independent activity of AT1Rs
[59]. These are known as molecule-speciﬁc effects, whereas the
Fig. 5. Attenuation of light-induced molecular changes by treatment with either valsartan or NAC. (A, B) The mRNA level of c-fosmeasured by quantitative real-time RT-PCR,
1 h after light exposure, was signiﬁcantly attenuated in the retinas of light-exposed mice treated with either (A) valsartan or (B) NAC, compared with vehicle-treated mice. (C,
D) The increase in the fasl mRNA level 6 h after light exposure was signiﬁcantly attenuated in the retinas of light-exposed mice treated with either (C) valsartan or (D) NAC,
compared with vehicle-treated mice. Valsartan was administered at 5 mg/kg and NAC was at 250 or 500 mg/kg. The NAC-induced suppression was dose-dependent (B, D).
NAC, N-acetyl-L-cysteine. n ¼ 6. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc test. **P o 0.01, *P o 0.05.
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AT1R-antagonizing effect is known as an ARB class-speciﬁc effect. In
this study, three different ARBs all exhibited dose-dependent effects
in preventing visual function impairment. Therefore, we conclude
that these are class-speciﬁc effects of the ARBs.
The protective effects of the ARBs against light-induced visual
function impairment, such as the suppression of the reduced a-wave
amplitudes in the ERG, were consistent with their effects on the
histological changes in the photoreceptor cells. Light-induced thin-
ning of the ONL and the photoreceptor cell layer was found to result
from photoreceptor cell apoptosis and shortening of the OS, which
contains the photosensitive discs, consistent with previous reports
[6,18]. These ﬁndings indicated that even the surviving photoreceptor
cells were affected and showed signs of degeneration. All of these
photoreceptor changes were attenuated by ARB treatment, indicating
that AT1R blockade promoted photoreceptor survival andmaintained
cell health after light stimulation. Fewer changes were observed in
the inner retina after light exposure, suggesting that the reduction in
b-wave amplitude may reﬂect the reduced electrical activity of the
downstream network of photoreceptor cells.
The induction of ROS in photoreceptor cells after light exposure
was also consistent with previous reports [15,60]. Because of the
extremely high oxygen gradient extending from the choroid to the
inner segment of the photoreceptors [11,60], it has been suggested
that the oxygen-consuming mitochondria in the inner segments
play a primary role in oxidative stress reactions of the outer retina
[12,60,61]. There are some reports suggesting that AT1R signaling
can stimulate mitochondrial oxidant release leading to energy
metabolism depression in renal and cardiovascular diseases
[55,58], suggesting that ARBs may function in part by suppressing
this pathway. Alternatively, a recent report suggests that nicoti-
namide adenine dinucleotide phosphate oxidase (Nox) enzymes
contribute to ROS generation in photoreceptor cells [60,62]. The
AT1R-induced ROS accumulation is reported to occur through the
action of Nox in vascular endothelial cells [63] and cardiac
ﬁbroblasts [64]. Our ﬁndings indicating that the ROS induction in
response to light is regulated by AT1R signaling raise the possibi-
lity that the Nox pathway is involved as well.
An increase in AP-1’s DNA-binding activity has been shown to be
a key event in regulating retinal photodamage [65]. The induction of
the mRNA for c-Fos, an AP-1 component, after light exposure was
also previously reported [18], consistent with results of the current
study. Upregulated c-Fos expression may also contribute to dysregu-
lated gene expression through AP-1. In our system the light-induced
c-fos upregulation was attenuated by treatment with either an ARB
or NAC, suggesting that these treatments may have suppressed
c-Fos-mediated dysregulated gene expression that contributes to
light-induced retinal damage. This idea is supported by the increased
mRNA levels of fasl, which was also found to be regulated down-
stream of both signaling pathways.
Photoaging involves the accumulated effects of daily light
exposure on tissues and organs over time [15,66,67]. In this study,
we showed that AT1R signaling was activated in the retina in
response to light stimulation. Because the pathogenesis of a
number of age-related diseases, such as hypertension and dia-
betes, involves the dysregulation of the RAS and its downstream
signaling pathways [33], the results of this study may lead to
further investigation on the involvement of RAS activation in
tissue aging caused by light exposure.
The limitations of this study include the fact that the model
was generated by an acute and intense light exposure, which
humans would not experience in daily life; therefore, the study
may not absolutely mimic the inﬂuence of light exposure in
humans. Mice have no macula in the retina, where photoreceptor
cells are concentrated, in contrast to humans; thus, the phenotype
of the light-exposed mice may not completely reﬂect the damage
in humans. In addition, the doses of ARBs and NAC used in this
study (the lowest doses per body weight used in this study were
approximately four or ﬁve times more than ordinary doses of
human use for treating hypertension by ARBs and for detoxiﬁca-
tion by NAC) may not be simply converted to estimate the effects
in humans, because there would be differences in the pharmaco-
kinetics between humans and mice, and the effect may not be
equal when using the same doses. Studies on therapeutic
approaches for light-induced retinal damage have focused largely
on treatment with neurotrophic factors, such as erythropoietin
[68], FGF [69], CNTF [70], and LIF [71], in addition to light-blocking
mechanisms [18–20]. In the current study, we prevented light-
induced retinal damage by suppressing dysregulated cell signaling.
This approach may show promise as a stand-alone therapy or as an
additional therapy for use in combination with trophic factors or
with light-blocking glasses and/or intraocular lenses, which are
currently used for cataract treatment.
Conclusion
We found that in vivo AT1R blockade in mice was an effective
therapeutic approach for protecting photoreceptor neurons from the
effects of light-induced cellular damage. ARB treatment suppressed
the elevation of ROS levels, resulting in reduced proapoptotic
signaling and increased survival of photoreceptor cells.
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